StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) shareholders

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Ownership

Who owns Oncotelic Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
9 buys · 0 sales
Net bought $61.28K

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Vuong TrieuCHAIRMAN AND CEO, Director, 10% owner119,134,22226.04%Oct 30, 2026
Anthony E. Maida IiiDIRECTOR AND CMO - TRANS. MED.1,137,3140.25%Jul 14, 2026
Seymour Howard FeinCRO/CMO––Jul 23, 2026
Saran SaundCBO16,457,4803.60%Jul 14, 2026
Amit B. ShahCFO378,8370.08%Jul 14, 2026
Steven W. KingDirector4,027,3510.88%Jul 21, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Oct 29, 2026Buy+1,044,990$0.02$17.76K95,481,309
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Oct 28, 2026Buy+312,000$0.02$5.77K94,436,319
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jul 1, 2026Buy+240,000$0.04$9.60K94,124,319
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jun 24, 2026Buy+115,000$0.05$5.75K93,884,319
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jun 23, 2026Buy+75,000$0.05$3.75K93,769,319
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jun 22, 2026Buy+65,000$0.05$3.25K93,694,319
Amit B. Shah
CFO
Jun 22, 2026Buy+20,000$0.05$1.00K378,837
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jun 17, 2026Buy+239,759$0.04$9.59K93,629,319
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jun 15, 2026Buy+96,000$0.05$4.80K93,389,560
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jul 10, 2025Buy+104,000$0.01$1.04K93,293,560
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jul 9, 2025Buy+1$0.01$093,293,561
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jul 8, 2025Buy+94,736$0.01$94793,388,297
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jan 31, 2025Buy+63,775$0.03$1.91K93,189,560
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jan 30, 2025Buy+100,003$0.03$3.00K93,125,785
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jan 29, 2025Buy+183,066$0.03$5.49K93,025,782
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Nov 22, 2024Buy+298,499$0.03$8.95K92,842,716
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Aug 23, 2024Buy+500,000$0.02$10.00K92,544,217
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jun 29, 2023Buy+425,000$0.02$8.50K92,044,217
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jun 28, 2023Buy+75,000$0.03$2.25K91,619,217
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jun 16, 2023Buy+100,000$0.03$3.00K91,544,217
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jun 14, 2023Buy+400,000$0.03$12.00K91,444,217
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
May 26, 2023Buy+126,888$0.03$3.81K91,044,217
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
May 2, 2023Buy+100,000$0.05$5.00K90,917,329
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Dec 6, 2022Buy+120,000$0.05$6.00K90,558,021
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Nov 22, 2022Buy+70,000$0.08$5.60K90,438,021
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Sep 26, 2022Buy+20,000$0.07$1.40K90,368,021
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Aug 25, 2022Buy+80,000$0.08$6.40K90,348,021
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Jul 8, 2021Award+259,302––90,527,323
Amit B. Shah
CHIEF FINANCIAL OFFICER
Jul 8, 2021Award+298,837––358,837
Saran Saund
CHIEF BUSINESS OFFICER
Jul 8, 2021Award+102,519––16,457,480
Anthony E. Maida Iii
CHIEF CLINICAL OFFICER, Director
Mar 31, 2021Conversion+938,646––1,137,314
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Mar 31, 2021Conversion+5,672,025––6,872,529
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Mar 31, 2021Conversion+13,849,161––16,780,384
Vuong Trieu
CHAIRMAN AND CEO, Director, 10% owner
Mar 31, 2021Conversion+74,455,719––90,268,021
Steven W. King
Director
Mar 31, 2021Conversion+3,291,720––3,330,647
Saran Saund
CHIEF BUSINESS OFFICER
Mar 31, 2021Conversion+16,354,961––16,354,961
Amit B. Shah
CHIEF FINANCIAL OFFICER
Nov 24, 2020Buy+8,220$0.19$1.56K60,000
Amit B. Shah
CHIEF FINANCIAL OFFICER
Nov 23, 2020Buy+20,088$0.19$3.82K51,780
Amit B. Shah
CHIEF FINANCIAL OFFICER
Nov 20, 2020Buy+31,692$0.20$6.34K31,692
Vuong Trieu
CHIEF EXECUTIVE OFFICER
Nov 19, 2020Buy+50,500$0.19$9.60K15,812,308
Chulho Park
CHIEF TECHNOLOGY OFFICER
Nov 19, 2020Buy+22,173$0.18$3.99K2,833,992
Vuong Trieu
CHIEF EXECUTIVE OFFICER
Mar 26, 2020Buy+3,000$0.12$36015,761,808
Matthew M. Loar
Chief Financial Officer
Apr 12, 2018Buy+250,000––300,000
Donald Rogers Reynolds
Director
Apr 12, 2018Buy+250,000––280,000
William D. Schwieterman
President and CEO, Director
Apr 12, 2018Buy+625,000––625,747
Donald Rogers Reynolds
Director
Dec 16, 2016Buy+12,700$0.34$4.32K12,700
Donald Rogers Reynolds
Director
Dec 16, 2016Buy+9,950$0.36$3.58K30,000
Donald Rogers Reynolds
Director
Dec 16, 2016Buy+7,350$0.35$2.57K20,050
Gerald McMahon PhD
Director
Jul 2, 2014Award+3,847––18,611
Gerald McMahon PhD
Director
Jan 2, 2014Award+3,584––14,764
Peter Langecker
Chief Executive Officer, Director
Aug 8, 2013Award+72,993––77,993
Gerald McMahon PhD
Director
Jul 1, 2013Award+7,407––11,180
Tamar D. Howson
Director
Jul 1, 2013Award+3,703––8,761
Peter Langecker
Chief Executive Officer, Director
Jun 28, 2013Buy+3,000$2.75$8.25K5,000
Peter Langecker
Chief Executive Officer, Director
Jun 25, 2013Buy+2,000$2.79$5.58K2,000
Tamar D. Howson
Director
Jan 2, 2013Award+1,886––5,058
Gerald McMahon PhD
Director
Jan 2, 2013Award+3,773––3,773
Tamar D. Howson
Director
Jul 2, 2012Award+18,148––38,060
Tamar D. Howson
Director
Jul 1, 2012Award+18,148––38,060
Tamar D. Howson
Director
Jan 2, 2012Award+10,101––19,912

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 1M shares a day
Change since last report
-56.7%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Oncotelic Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 12 shares on Sep 17, 2026 over the last 90 days.

See a number that looks wrong?